Aktie 4123 CENTER LABORATORIES, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Center Laboratories, Inc.

Aktien

4123

TW0004123005

4123

Schlusskurs Taipei Exchange
Andere Börsenplätze
 00:00:00 24.04.2024 		% 5 Tage % 1. Jan.
43.85 TWD +1.04% Intraday Chart für Center Laboratories, Inc. +2.10% -1.02%
19.03. Center Laboratories, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI
06.02. Center Laboratories, Inc. gibt bekannt, dass Wang, Su-Chi gleichzeitig die Position des Chief Investment Officer und des Chief Operating Officer innehat CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Center Laboratories, Inc. cancelled the transaction announced on June 20, 2023
Center Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Mycenax Biotech Inc. announced that it expects to receive funding from Center Laboratories, Inc., JCR Pharmaceuticals Co., Ltd., Taiwan BioVenture Company, Jason Technologies Ltd
Center Laboratories, Inc. Announces Wang, Su-Chi Holds Concurrent Position as Chief Investment Officer and Chief Operating Officer
Center Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Center Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Center Laboratories, Inc. Announces Cash Dividend Distribution for the Year 2022, Payable on October 13, 2023
Center Laboratories, Inc. announced a financing transaction
Center Laboratories, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Center Laboratories, Inc. Proposes Cash Dividend for the Period from January 1, 2022 to December 31, 2022
Center Laboratories, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
Center Laboratories, Inc. Announces Executive Appointments
Center Laboratories, Inc. Announces Management Changes
Center Laboratories, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Bao Pharma announced that it has received $100 million in funding from Shenzhen Oriental Fortune Capital Co., Ltd., Finnova Capital, Haitong Innovation Private Fund Management Co., Ltd., Shanghai Sun Rock Capital Management Co., Ltd., Center Laboratories, Inc.
Center Laboratories, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Center Laboratories : To announce the ex-rights and dividend record date and the closure period for the conversion of CB4 and CB5
Center Laboratories, Inc. Announces Cash Dividend Distribution for the Year 2021
Center Laboratories : Amendment on the Company's 2021 Annual Report
Center Laboratories : Announcement on the change of internal audit officer
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. 4123 Aktie
  4. Nachrichten Center Laboratories, Inc.
  5. Andere Sprachen